Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

CJC-1295 vs Hexarelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

CJC-1295 and Hexarelin share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Phase 2 (not approved)). On the catalogued data layer CJC-1295 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CJC-1295's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

CJC-1295

Anecdotal + Phase 2 (DAC)

Hexarelin

Phase 2 (not approved)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

CJC-1295 Hexarelin
Class GHRH analog (no-DAC or DAC forms) GHRP; potent ghrelin receptor agonist
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life GHS-R1a agonist; more potent GH release than other GHRPs
Route SC injection SC / Intranasal
Half-life No-DAC ~30 min / DAC ~8 days ~1 hr
Dosage (research) No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) 100-200 mcg SC 1-2x daily (short cycles)
Evidence tier Anecdotal + Phase 2 (DAC) Phase 2 (not approved)
Research depth 44 indexed (PubMed 34 · CT 1 · EPMC 9) 158 indexed (PubMed 141 · CT 0 · EPMC 17)
Availability Compounding Restricted Research Chemical
Reported risks Water retention; numbness/tingling; elevated IGF-1; injection site reactions Cortisol/prolactin elevation; pituitary desensitization

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick CJC-1295 or Hexarelin?

CJC-1295 and Hexarelin share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Phase 2 (not approved)). On the catalogued data layer CJC-1295 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CJC-1295's evidence base is currently denser.

What is the difference between CJC-1295 and Hexarelin?

CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; Hexarelin, ~1 hr. Routes in published studies: CJC-1295, SC injection; Hexarelin, SC / Intranasal.

Which has stronger evidence, CJC-1295 or Hexarelin?

CJC-1295 and Hexarelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 44 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies.

Which is more accessible, CJC-1295 or Hexarelin?

Neither CJC-1295 nor Hexarelin is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; Hexarelin, Research Chemical. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are CJC-1295 and Hexarelin ever combined?

CJC-1295 and Hexarelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…